Bumetanid etkileşimleri

Drug Interactions Drugs with Ototoxic Potential (see WARNINGS ) Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. (Bumetanid etiketi, İlaç etkileşimleri)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. (Arsenik trioksit etiketi, Uyarılar ve önlemler)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

In the DIAMOND trials, 1252 patients were treated with dofetilide and diuretics concomitantly, of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics. (Dofetilid etiketi, İlaç etkileşimleri)

Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). (Droperidol etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

…sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Enalaprilat etiketi, Uyarılar)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

Like other diuretics it may precipitate hepatic coma and death. (Etakrinik asit etiketi, Uyarılar)

Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. (Follitropin etiketi, Uyarılar ve önlemler)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

Drug Interactions Drugs with Ototoxic Potential (see WARNINGS ) Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. (Bumetanid etiketi, İlaç etkileşimleri)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

Avoid diuretics or laxatives in patients with diarrhea. (İrinotekan etiketi, Uyarılar ve önlemler)

Diuretics Eplerenone Contraindicated during and 2 weeks after TOLSURA treatment. (İtrakonazol etiketi, İlaç etkileşimleri)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

…sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Kinapril etiketi, Uyarılar)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Koriogonadotropin alfa etiketi, Uyarılar)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (Minoksidil etiketi, Kutulu uyarı)

Drug Interactions Drugs with Ototoxic Potential (see WARNINGS ) Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. (Bumetanid etiketi, İlaç etkileşimleri)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

Drug Interactions Drugs with Ototoxic Potential (see WARNINGS ) Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. (Bumetanid etiketi, İlaç etkileşimleri)

The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) (Potasyum sitrat etiketi, İlaç etkileşimleri)

Thus, probenecid should not be administered concurrently with bumetanide. (Bumetanid etiketi, İlaç etkileşimleri)

Thus, probenecid should not be administered concurrently with bumetanide. (Bumetanid etiketi, İlaç etkileşimleri)

Potassium-Sparing Diuretics Cyclosporine should not be used with potassium-sparing diuretics because hyperkalemia can occur. (Siklosporin etiketi, İlaç etkileşimleri)

Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

Drug Interactions Drugs with Ototoxic Potential (see WARNINGS ) Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. (Bumetanid etiketi, İlaç etkileşimleri)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

…Precautions (5.6) and Adverse Reactions (6) ]. β-blockers, such as propranolol Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline… (Adrenalin etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. (Allopurinol etiketi, Uyarılar ve önlemler)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (Alogliptin ve metformin etiketi, İlaç etkileşimleri)

Give special attention to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics and laxatives. (Amiodaron etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Arformoterol etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Like other members of this class of diuretics, bumetanide probably shares this risk. (Bumetanid etiketi, Uyarılar)

…this product or any of its ingredients Ask a doctor before use if stomach bleeding warning applies to you you have a history of stomach problems, such as heartburn you are taking a diuretic you have high blood pressure, heart disease, liver cirrhosis, or kidney disease you have asthma Ask a doctor or pharmacist before use if you are taking a prescription drug… (Aspirin etiketi, Uyarılar)

Diuretics The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. (Aspirin ve dipiridamol etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Diuretics Clinical Impact : Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Belladonna ve afyon etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin ve nalokson etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Butalbital, aspirin, kafein ve kodein etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Butalbital, parasetamol, kafein ve kodein etiketi, İlaç etkileşimleri)

…(45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once daily for 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12% [↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days)… (Dapagliflozin etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Dapagliflozin ve metformin etiketi, Uyarılar ve önlemler)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Dekslansoprazol etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with NORPRAMIN. (Desipramin etiketi, Uyarılar)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Desmopressin etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3) ] . (Desvenlafaksin etiketi, Uyarılar ve önlemler)

The concomitant administration of thiazides or other diuretics may potentiate the hyperglycemic and hyperuricemic effects of PROGLYCEM. (Diazoksit etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, patients who are volume depleted, and the elderly. (Diflunisal etiketi, Uyarılar)

Prevention of hypokalemia requires particular attention in the following conditions: patients receiving digitalis and diuretics for congestive heart failure, hepatic cirrhosis and ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, certain diarrheal states, or other states where hypokalemia is thought to represent particular… (Bumetanid etiketi, Uyarılar)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Diklofenak etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Diklofenak ve misoprostol etiketi, Uyarılar ve önlemler)

Drugs that Cause Hypokalemia The risk of hypokalemia is greater with coadministration of KEVEYIS and other drugs that can cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillins, and theophylline) [see Warnings and Precautions (5.3) ] . (Diklorfenamid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Risk may be increased when used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Dokserkalsiferol etiketi, Uyarılar ve önlemler)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (Drospirenon ve etinilestradiol etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Duloksetin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Empagliflozin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Empagliflozin ve metformin etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Epoprostenol etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Esomeprazol etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Essitalopram etiketi, Uyarılar ve önlemler)

Patients at greater risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (Etodolak etiketi, Uyarılar)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (Fenelzin etiketi, Uyarılar)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fenoprofen etiketi, Uyarılar ve önlemler)

…treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance. (Fentanil etiketi, Uyarılar ve önlemler)

In addition, when phentermine and topiramate extended-release capsules are used in conjunction with nonpotassium sparing diuretics this may further potentiate potassium-wasting. (Fentermin ve topiramat etiketi, Uyarılar ve önlemler)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (Fludrokortizon etiketi, İlaç etkileşimleri)

An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics. (Flukonazol etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fluoksetin etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Flurbiprofen etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Flutikazon ve salmeterol etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Fluvoksamin etiketi, Uyarılar ve önlemler)

• Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Formoterol etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity. (Foskarnet etiketi, İlaç etkileşimleri)

In these test animals bumetanide was 5 to 6 times more potent than furosemide and, since the diuretic potency of bumetanide is about 40 to 60 times furosemide, it is anticipated that blood levels necessary to produce ototoxicity will rarely be achieved. (Bumetanid etiketi, Uyarılar)

…danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline),… (Glimepirid etiketi, İlaç etkileşimleri)

…may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic… (Glipizid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (Haloperidol etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Example: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidrokodon etiketi, İlaç etkileşimleri)

Diuretics : Hydrocodone may reduce the efficacy of diuretics. (Hidrokodon ve homatropin etiketi, İlaç etkileşimleri)

Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs (see PRECAUTIONS: Drug Interactions). (Hidrokodon ve ibuprofen etiketi, Uyarılar)

Diuretics : Hydrocodone may reduce the efficacy of diuretics. (Hidrokodon ve klorfeniramin etiketi, İlaç etkileşimleri)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidrokodon ve parasetamol etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidromorfon etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (İbuprofen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (İbuprofen ve famotidin etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with imipramine hydrochloride tablets. (İmipramin etiketi, Uyarılar)

Indomethacin Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity. (Bumetanid etiketi, İlaç etkileşimleri)

Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (İnsülin aspart etiketi, İlaç etkileşimleri)

Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (İnsülin degludek etiketi, İlaç etkileşimleri)

Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (İnsülin detemir etiketi, İlaç etkileşimleri)

Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents… (İnsülin glarjin etiketi, İlaç etkileşimleri)

Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (İnsülin lispro etiketi, İlaç etkileşimleri)

Diuretics The electrocardiogram (ECG) changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded. (İpratropium ve salbutamol etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Kalsiyum klorür etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Kanagliflozin etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (Karbamazepin etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Diuretics eplerenone The potential increase in plasma concentrations of eplerenone when coadministered with ketoconazole tablets may increase the risk of hyperkalemia and hypotension. (Ketokonazol etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (Ketorolak etiketi, Uyarılar ve önlemler)

Drugs that alkalinize the urine ( carbonic-anhydrase inhibitors, sodium bicarbonate, thiazide diuretics ) reduce renal elimination of quinidine. (Kinidin etiketi, İlaç etkileşimleri)

Consider use of diuretics and/or albumin. (Klofarabin etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Hypokalemia can result from diuretic therapy, diarrhea, and other causes. (Klozapin etiketi, Uyarılar ve önlemler)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Kodein etiketi, İlaç etkileşimleri)

Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (Kolestiramin etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Lansoprazol etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Levomilnasipran etiketi, Uyarılar ve önlemler)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Levorfanol etiketi, İlaç etkileşimleri)

Diuretics The ECG changes or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop and thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Levosalbutamol etiketi, İlaç etkileşimleri)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (Linezolid etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Lithium Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Mefenamik asit etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Meloksikam etiketi, Uyarılar ve önlemler)

Closely monitor patients with risk factors for development of prolonged QT interval (e.g., cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction. (Metadon etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (Milnasipran etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5) ] . (Mirtazapin etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Morfin etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Nabumeton etiketi, Uyarılar)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Nalbufin etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Naproksen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (Naproksen ve esomeprazol etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (Nimodipin etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Oksaprozin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksikodon etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksikodon ve parasetamol etiketi, İlaç etkileşimleri)

Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksimorfon etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Olanzapin ve fluoksetin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oliseridin etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Omeprazol etiketi, Uyarılar ve önlemler)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Omeprazol ve sodyum bikarbonat etiketi, Uyarılar ve önlemler)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Pantoprazol etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Parasetamol ve ibuprofen etiketi, Uyarılar ve önlemler)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Parasetamol ve kodein etiketi, İlaç etkileşimleri)

The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Parikalsitol etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (Paroksetin etiketi, Uyarılar ve önlemler)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Pentazosin ve nalokson etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Petidin etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

…danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline),… (Pioglitazon ve glimepirid etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Piroksikam etiketi, Uyarılar ve önlemler)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (Potasyum iyodür etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Proklorperazin etiketi, Önlemler)

Diuretics : Codeine may reduce the efficacy of diuretics. (Prometazin ve kodein etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Rabeprazol etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Salbutamol etiketi, İlaç etkileşimleri)

• Diuretics: Use with caution. (Salmeterol etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (Salsalat etiketi, Uyarılar)

Diuretics: Nephrotoxicity has been reported with concomitant administration of cephalosporins with potent diuretics such as furosemide. (Sefepim etiketi, İlaç etkileşimleri)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (Seftazidim etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia , heart failure, liver dysfunction, those taking diuretics, ACE inhibitors or the ARBs, and the elderly. (Selekoksib etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Sertralin etiketi, Uyarılar ve önlemler)

…inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity ● Amiodarone… (Siklofosfamid etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume depleted may be at greater risk for developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Sitalopram etiketi, Uyarılar ve önlemler)

Increase the dose of diuretics as needed [see Adverse Reactions (6) ] . (Sodyum zirkonyum siklosilikat etiketi, Uyarılar ve önlemler)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (Sotalol etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, patients who are volume-depleted, and the elderly. (Sulindak etiketi, Uyarılar)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Sumatriptan ve naproksen etiketi, Uyarılar ve önlemler)

Prolonged Neuromuscular Block in Patients with Hypokalemia or Hypocalcemia Neuromuscular blockade may be prolonged in patients with hypokalemia (e.g., after severe vomiting, diarrhea, digitalisation and diuretic therapy) or hypocalcemia (e.g., after massive transfusions). (Süksinilkolin etiketi, Uyarılar ve önlemler)

Drug Interactions In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. (Sülfametoksazol ve trimetoprim etiketi, İlaç etkileşimleri)

Concomitant use of agents associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) may increase the risk for hyperkalemia [see Adverse Reactions ( 6.1 )] . (Takrolimus etiketi, Uyarılar ve önlemler)

…use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ] Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tapentadol etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Use of tolmetin may blunt the CV effects of several therapeutic agents used to treat these medical conditions [e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers (ARBs)] (see PRECAUTIONS: Drug Interactions ). (Tolmetin etiketi, Uyarılar)

Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. (Tolvaptan etiketi, Uyarılar ve önlemler)

Like other members of this class of diuretics, bumetanide probably shares this risk. (Bumetanid etiketi, Uyarılar)

Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. (Toremifen etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tramadol etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tramadol ve parasetamol etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations (8.5) ] . (Trazodon etiketi, Uyarılar ve önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Trifluoperazin etiketi, Önlemler)

• Diuretics: Use with caution. (Umeklidinyum ve vilanterol etiketi, İlaç etkileşimleri)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Venlafaksin etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations ( 8.5 )] . (Vilazodon etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. (Vortioksetin etiketi, Uyarılar ve önlemler)

Hypokalemia may result from diuretic therapy, diarrhea, and other causes. (Ziprasidon etiketi, Uyarılar ve önlemler)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (Zoledronik asit etiketi, Uyarılar ve önlemler)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (Akarboz etiketi, İlaç etkileşimleri)

Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure. (Ambrisentan etiketi, Uyarılar ve önlemler)

Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure. (Bosentan etiketi, Uyarılar ve önlemler)

Allergy to Sulfonamides Patients allergic to sulfonamides may show hypersensitivity to bumetanide. (Bumetanid etiketi, Uyarılar)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

Allergy to Sulfonamides Patients allergic to sulfonamides may show hypersensitivity to bumetanide. (Bumetanid etiketi, Uyarılar)

Allergy to Sulfonamides Patients allergic to sulfonamides may show hypersensitivity to bumetanide. (Bumetanid etiketi, Uyarılar)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Dosetaksel etiketi, Uyarılar ve önlemler)

Hypokalemia and Hypomagnesemia with Potassium-Depleting Diuretics Hypokalemia or hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. (Dronedaron etiketi, Uyarılar ve önlemler)

In addition to discontinuation of the drug, diuretic therapy may be required. (Esterifiye östrojenler ve metiltestosteron etiketi, Uyarılar)

Supplemental potassium and/or spironolactone may prevent hypokalemia and metabolic alkalosis in these patients. (Bumetanid etiketi, Uyarılar)

…clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives… (Finasterid etiketi, İlaç etkileşimleri)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (Flekainid etiketi, İlaç etkileşimleri)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Glibenklamid etiketi, İlaç etkileşimleri)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Glibenklamid ve metformin etiketi, İlaç etkileşimleri)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Glipizid ve metformin etiketi, Önlemler)

Allergy to Sulfonamides Patients allergic to sulfonamides may show hypersensitivity to bumetanide. (Bumetanid etiketi, Uyarılar)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (İmatinib etiketi, Uyarılar ve önlemler)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (Kalsiyum glukonat etiketi, İlaç etkileşimleri)

Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy. (Kortikotropin etiketi, İlaç etkileşimleri)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Linagliptin ve metformin etiketi, İlaç etkileşimleri)

Kıvrım (loop) diüretiklerinin ve tiyazid diüretiklerin uzun süreli kullanımı idrarla magnezyum kaybını artırır. (NIH Office of Dietary Supplements, Magnesium)

Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (Masitentan etiketi, Uyarılar ve önlemler)

Allergy to Sulfonamides Patients allergic to sulfonamides may show hypersensitivity to bumetanide. (Bumetanid etiketi, Uyarılar)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Metformin etiketi, İlaç etkileşimleri)

Amphotericin B injection and potassium-depleting agents : When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (Metilprednizolon etiketi, İlaç etkileşimleri)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

Supplemental potassium and/or spironolactone may prevent hypokalemia and metabolic alkalosis in these patients. (Bumetanid etiketi, Uyarılar)

These drugs include: aspirin, phenylbutazone, sulfonamides, indomethacin, thiazide diuretics, furosemide and ethacrynic acid. (Penisilin G etiketi, İlaç etkileşimleri)

Pentoxifylline extended-release tablets have been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics, without observed problems. (Pentoksifilin etiketi, İlaç etkileşimleri)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Pioglitazon ve metformin etiketi, İlaç etkileşimleri)

Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics. (Piperasilin ve tazobaktam etiketi, Uyarılar ve önlemler)

Supplemental potassium and/or spironolactone may prevent hypokalemia and metabolic alkalosis in these patients. (Bumetanid etiketi, Uyarılar)

Supplemental potassium and/or spironolactone may prevent hypokalemia and metabolic alkalosis in these patients. (Bumetanid etiketi, Uyarılar)

Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizolon etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (Regüler insülin (insan) etiketi, İlaç etkileşimleri)

Supplemental potassium and/or spironolactone may prevent hypokalemia and metabolic alkalosis in these patients. (Bumetanid etiketi, Uyarılar)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Saksagliptin ve metformin etiketi, İlaç etkileşimleri)

…Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine). (Sidofovir etiketi, İlaç etkileşimleri)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Sitagliptin ve metformin etiketi, İlaç etkileşimleri)

Supplemental potassium and/or spironolactone may prevent hypokalemia and metabolic alkalosis in these patients. (Bumetanid etiketi, Uyarılar)

Allergy to Sulfonamides Patients allergic to sulfonamides may show hypersensitivity to bumetanide. (Bumetanid etiketi, Uyarılar)

Allergy to Sulfonamides Patients allergic to sulfonamides may show hypersensitivity to bumetanide. (Bumetanid etiketi, Uyarılar)

There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (Terbinafin etiketi, İlaç etkileşimleri)

Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents ( i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (Triamsinolon etiketi, İlaç etkileşimleri)

Allergy to Sulfonamides Patients allergic to sulfonamides may show hypersensitivity to bumetanide. (Bumetanid etiketi, Uyarılar)

Anticoagulants Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. (Bumetanid etiketi, İlaç etkileşimleri)

Anticoagulants Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. (Bumetanid etiketi, İlaç etkileşimleri)

Anticoagulants Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. (Bumetanid etiketi, İlaç etkileşimleri)

Anticoagulants Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. (Bumetanid etiketi, İlaç etkileşimleri)

Anticoagulants Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. (Bumetanid etiketi, İlaç etkileşimleri)

Anticoagulants Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. (Bumetanid etiketi, İlaç etkileşimleri)

Anticoagulants Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. (Bumetanid etiketi, İlaç etkileşimleri)

Anticoagulants Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. (Bumetanid etiketi, İlaç etkileşimleri)

ECG intervals (PR, QRS, and QT) were not affected by concurrent mexiletine and digoxin, diuretics, or propranolol. (Meksiletin etiketi, İlaç etkileşimleri)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronat etiketi, İlaç etkileşimleri)

Anticoagulants Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. (Bumetanid etiketi, İlaç etkileşimleri)

Anticoagulants Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. (Bumetanid etiketi, İlaç etkileşimleri)